


BMS-192364

Cat. No.:	HY-114865		
CAS No.:	202822-21-7		
Molecular Formula:	C ₁₅ H ₉ ClF ₃ N ₃ O ₂		
Molecular Weight:	355.7		
Target:	RGS Protein; Calcium Channel		
Pathway:	GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (281.14 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
	Preparing Stock Solutions	1 mM	5 mM	10 mM
		2.8114 mL	14.0568 mL	28.1136 mL
		0.5623 mL	2.8114 mL	5.6227 mL
		0.2811 mL	1.4057 mL	2.8114 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (7.03 mM); Clear solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (7.03 mM); Clear solution; Need ultrasonic			

BIOLOGICAL ACTIVITY

Description	BMS-192364 is targeting the G _q -RGS interaction to produce an inactive G _q -RGS complex. BMS-192364 reduces urinary bladder contraction and exert RGS-agonist properties by increasing the action of GAPs on Gq proteins. BMS-192364 inhibits calcium flux ^{[1][2][3]} .
--------------------	--

REFERENCES

- [1]. Kevin Fitzgerald, et al. Chemical genetics reveals an RGS/G-protein role in the action of a compound. PLoS Genet. 2006 Apr;2(4):e57.
- [2]. Maciej Salaga, et al. RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. Bioessays. 2016

Apr;38(4):344-54.

[3]. David P Basile, et al. A GAP in our knowledge of vascular signaling in acute kidney injury. Kidney Int. 2011 Aug;80(3):233-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA